Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| XBiotech Inc.XBIT · Entity 7044 | Chief Scientific Officer | February 10, 2023 | February 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
XBiotech Inc.
Report date February 10, 2023 · Filed February 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.84 · Expires 2033-02-09 | Direct | 100,000 |
Reported balance
After 2023-02-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-10 · Grant · Acquired 100,000 · Balance 100,000 F1: On February 10, 2023 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in four equal portions in two years commencing as of August 10, 2023, with an expiry of ten years from the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 10, 2023 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in four equal portions in two years commencing as of August 10, 2023, with an expiry of ten years from the Grant Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2023 Filed Feb 17, 2023 20:00 UTC | XBiotech Inc. XBIT · Entity 7044 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001209191-23-010932 · doc4.xml · derivative · entry 1 SHIVASWAMY SUSHMA · CIK 0001638762 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-02-09 F1 · derivative.exercise_date: On February 10, 2023 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in four equal portions in two years commencing as of August 10, 2023, with an expiry of ten years from the Grant Date. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 16:13 UTC | XBiotech Inc. XBIT · Entity 7044 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $12.67 | $0.00 |
DisclosureSEC source: 0001209191-21-066404 · doc4.xml · derivative · entry 1 SHIVASWAMY SUSHMA · CIK 0001638762 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-11-19 Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 16:22 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionStock Options · Derivative | 20,668 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-20-050693 · doc4.xml · derivative · entry 6 SHIVASWAMY SUSHMA · CIK 0001638762 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stocks · 20,668 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 16:22 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Shares | 20,668 | $20.00 | $413,360.00 |
DisclosureSEC source: 0001209191-20-050693 · doc4.xml · nonDerivative · entry 4 SHIVASWAMY SUSHMA · CIK 0001638762 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 16:22 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionCommon Shares | 20,668 | $7.50 | $155,010.00 |
DisclosureSEC source: 0001209191-20-050693 · doc4.xml · nonDerivative · entry 3 SHIVASWAMY SUSHMA · CIK 0001638762 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2020 Filed Sep 16, 2020 16:22 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionStock options · Derivative | 19,332 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-20-050693 · doc4.xml · derivative · entry 5 SHIVASWAMY SUSHMA · CIK 0001638762 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stocks · 19,332 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2020 Filed Sep 16, 2020 16:22 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Shares | 19,332 | $20.01 | $386,833.32 |
DisclosureSEC source: 0001209191-20-050693 · doc4.xml · nonDerivative · entry 2 SHIVASWAMY SUSHMA · CIK 0001638762 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| September 10, 2020 Filed Sep 16, 2020 16:22 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionCommon Shares | 19,332 | $7.50 | $144,990.00 |
DisclosureSEC source: 0001209191-20-050693 · doc4.xml · nonDerivative · entry 1 SHIVASWAMY SUSHMA · CIK 0001638762 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 15:05 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionStock Option · Derivative | 100,000 | $0.00 Strike: $10.36 | $0.00 |
DisclosureSEC source: 0001209191-19-055793 · doc4.xml · derivative · entry 1 SHIVASWAMY SUSHMA · CIK 0001638762 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-11-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2019 Filed Mar 4, 2019 16:13 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionStock options · Derivative | 4,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001209191-19-015553 · doc4.xml · derivative · entry 3 SHIVASWAMY SUSHMA · CIK 0001638762 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stocks · 4,500 shares Expires 2019-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2019 Filed Mar 4, 2019 16:13 UTC | XBiotech Inc. XBIT · Entity 7044 | SaleCommon Stock | 4,500 | $10.00 | $45,000.00 |
DisclosureSEC source: 0001209191-19-015553 · doc4.xml · nonDerivative · entry 2 SHIVASWAMY SUSHMA · CIK 0001638762 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| February 07, 2019 Filed Mar 4, 2019 16:13 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionCommon Stock | 4,500 | $2.50 | $11,250.00 |
DisclosureSEC source: 0001209191-19-015553 · doc4.xml · nonDerivative · entry 1 SHIVASWAMY SUSHMA · CIK 0001638762 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2019 Filed Mar 4, 2019 16:51 UTC | XBiotech Inc. XBIT · Entity 7044 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $5.26 | $0.00 |
DisclosureSEC source: 0001209191-19-015702 · doc4.xml · derivative · entry 1 SHIVASWAMY SUSHMA · CIK 0001638762 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-01-04 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 07:14 UTC | XBiotech Inc. XBIT · Entity 7044 | GrantStock Option · Derivative | 150,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001209191-17-062227 · doc4.xml · derivative · entry 1 SHIVASWAMY SUSHMA · CIK 0001638762 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-11-20 F1 · derivative.exercise_date: On November 20, 2017 (the Grant Date) the reporting person was granted incentive stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in three equal annual installments commencing as of the first anniversary of the Grant Date with an expiry of ten years from the Grant Date. Read SEC document |
| June 19, 2017 Filed Jun 23, 2017 14:59 UTC Amendment | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionStock Option · Derivative | 50,000 | $4.24 Strike: $4.24 | $212,000.00 |
DisclosureSEC source: 0001209191-17-041625 · doc4a.xml · derivative · entry 1 SHIVASWAMY SUSHMA · CIK 0001638762 · VP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2017 Filed Jun 23, 2017 14:15 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionStock Option · Derivative | 50,000 | $4.24 Strike: $4.24 | $212,000.00 |
DisclosureSEC source: 0001209191-17-041608 · doc4.xml · derivative · entry 1 SHIVASWAMY SUSHMA · CIK 0001638762 · VP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On September 14, 2016 (the Grant Date) Fabrizio Bonanni was granted nonstatutory stock options (the Options) under the Company's 2015 Equity Incentive Plan to purcahse shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market, with an expiry of ten years from the Grant Date. Half of the Options vest on December 20, 2016 and another half of the Options vest on June 20, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.